Beigene Ltd
Community score
moreBeiGene Ltd. was incorporated in 2010 with its headquarters located in Beijing, China. Operating in the biotechnology and pharmaceutical industry, the company's core business segments involve the discovery, development, manufacturing, and commercialization of innovative molecularly targeted and immuno-oncology drugs for cancer treatment. Although BeiGene Ltd. is not associated with conventional consumer brands, it has developed pharmaceutical products such as BRUKINSA® (zanubrutinib), used to treat mantle cell lymphoma (MCL), and tislelizumab, a PD-1 antibody indicated for various tumor types. Its products and services have a global reach, with significant markets that include China, the United States, and several European countries. (Powered by AI)
Around 2 billion (Bn) people worldwide lack access to essential medications1;p1. At least 10% of the household budget of over 800 million people goes into healthcare expenditure, and 100 Mn people are pushed into extreme poverty due to unaffordabl...
Research and development (R&D) investments are crucial to developing drugs & vaccines that improve & save people's lives1. Immune checkpoint inhibitors (ICPI) have had tremendous success in various cancer treatments and are the most well-establish...
To ensure strong institutions and the well-being of society, governments spend a considerable amount of the state's budget on public goods and services, which are funded through taxes paid by individuals and corporations1. Corporate taxes accounte...
Globally, an estimated 80% of wastewater is discharged without proper treatment1. Water pollution causes algal blooms in the aquatic environment, resulting in a fast rise in nutrients that promote plant and algae development, lowering oxygen level...